Introduction
============

Congenital adrenal hyperplasia (CAH) is one of the most severe disorders of metabolism with an overall incidence of approximately 1:15,000 worldwide ([@bib1]). CAH encompasses a group of enzymatic deficiencies of cortisol synthesis, inherited in an autosomal recessive manner. Defective cortisol production results in negative feedback at the hypothalamus and pituitary gland, leading to excessive secretion of corticotrophin-releasing hormone and adrenocorticotropic hormone (ACTH), respectively. Increased levels of ACTH are not only unable to compensate for the deficient cortisol synthesis, but their trophic effects also produce adrenal gland enlargement ([@bib2]).

Pathologically, CAH is mainly caused by an inborn error of steroid synthesis. Six cytochrome P450 (CYP) enzymes including CYP11A1, CYP11B1, CYP11B2, CYP17A1, CYP19A1 and CYP21A2 are involved in the synthesis of steroid hormones. Although deficiencies of any of these enzymes can result in CAH ([@bib3]), CYP21A2 deficiency (21OHD) accounts for up to 95% of all CAH cases ([@bib4]). The *CYP21A2* gene is located on 6p21.3, approximately 30 kb from its pseudogene (*CYP21A1P*). *CYP21A2* and *CYP21A1P* share approximately 98% homology in their exons and 96% homology in their introns; therefore, a high frequency of recombination events may occur between the gene and pseudogene, leading to varying degrees of CYP21A2 enzymatic deficiency. Complete deficiency of CYP21A2 activity leads to both glucocorticoid and mineralocorticoid deficiencies, as well as severe adrenal-derived androgen excess, resulting in the virialized external genitalia of newborn girls. Compared to CYP21A2-related disorders, CYP17A1 deficiency is rare. The *CYP17* gene is located on chromosome 10q24-q25 and encodes 17α-hydroxylase, which catalyzes the 17α-hydroxylation of pregnenolone and progesterone and the 17,20-cleavage of the corresponding hydroxylated steroids ([@bib5]). CYP17A1 deficiency leads to the impaired synthesis of both glucocorticoids and androgen, resulting in increased ACTH secretion. Patients present with hypertension, hypokalemia and hypogonadism. Both 46, XY and 46, XX individuals have feminine external genitalia and present with amenorrhea and absent secondary sexual characteristics during puberty ([@bib2]).

Adrenal myelolipomas are rare, benign and endocrinologically inactive neoplasms composed of mature fat tissue and mixed myeloid and erythroid tissue ([@bib6]). They account for approximately 8% of adrenal incidentalomas ([@bib6]). In most cases, adrenal myelolipomas are unilateral and rarely exceed 4 cm. However, very large and bilateral myelolipomas have been reported, especially in the setting of CAH ([@bib7]). Although these tumors are benign, huge masses can produce symptoms such as flank pain and abdominal discomfort because of rupture, hemorrhage or necrosis ([@bib7]). Some patients with giant adrenal myelolipomas may present with even more severe symptoms, including hematuria, renovascular hypertension and surgical emergencies such as retroperitoneal hemorrhage ([@bib8]). CAH and Cushing's syndrome are two of the most common causes of adrenal myelolipomas ([@bib9]), and 4% of patients with CAH will develop a myelolipoma ([@bib10]). In this report, we describe two adult families with CAH-associated giant adrenal myelolipomas secondary to compound heterozygous mutations in *CYP21A2* and *CYP17A1* genes.

Materials and methods
=====================

Patients
--------

A total of 15 individuals from two unrelated families were sequenced to evaluate whether they carried the mutations or not. Among them, 14 individuals were identified with either *CYP21A2* or *CYP17A1* mutations. Of note, five patients were found with adrenal myelolipomas. The medical records including CT or MRI scan and laboratory/pathological examinations, as well as gene sequencing results were collected and analyzed. Additional information regarding their family history was obtained by further interviewing.

Compliance with ethical standards
---------------------------------

All procedures involving human participants were carried out in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Daping Hospital of Third Military Medical University waived institutional review board approval for the study; however, written informed consent for the use of medical records and related images was obtained from the patients.

Genetic analysis
----------------

Total DNA isolated from the peripheral blood of the two probands was screened for potential mutations in the following susceptibility genes of CAH: *CYP21A2*, *CYP11B1*, *CYP17A1*,*HSD17B3*,*HSD3B2*, *ARMC5* and *STAR* using Target Capture-Based Deep Sequencing (AmCare Genomic Laboratory, Guangzhou, Guangdong, China). Briefly, the process included fragmentation and construction of a genomic DNA, hybridization with custom made probe library (Nimblegen, Roche) to capture the genes of interested. The sequencing was carried out on NGS platform (HiSeq X system; Illumina) with PEx150 read length according to the manufactory's specification. The bioinformatics analysis was performed with in-house pipeline to identify rare or novel variants with Gnomad, HMGD, ClinVar, dbSNP for filtering and computational prediction algorithms, PolyPhen-2, SIFT and MutationTaster, for pathogenesis evaluation. After the identification of the variants in the proband, family co-segregation analyses were performed using Sanger sequencing. The corresponding primers were designed by Primer 3.0 and available upon request. The final pathogenicity of the variants was estimated using the American College of Medical Genetics and Genomics guidelines.

Results
=======

Clinical features of the patients
---------------------------------

### Family 1

A 59-year-old man was referred to our hospital in April 2012 with abdominal pain. CT revealed low attenuated masses in both adrenal glands ([Fig. 1A](#fig1){ref-type="fig"}). On admission, his blood pressure was 132/78 mmHg and heart rate was 78 beats/min. His physical examination was unremarkable, revealing no signs of Cushing's syndrome, hyperaldosteronism or pheochromocytoma. Laboratory results demonstrated elevated levels of 17-hydroxycorticosteroid (17-OH; 38.5 μmol/24 h, normal 8.3--33.2 μmol/24 h) and 17-ketosteroid (7-KS; 98.8 μmol/24 h, normal 20.8--76.3 μmol/24 h). On April 26, 2012, the patient underwent open bilateral adrenalectomies. Intraoperative findings revealed a 1.56 kg mass in the left adrenal and a 3.05 kg mass in the right adrenal ([Fig. 1A](#fig1){ref-type="fig"}, right lower corner). Pathology results confirmed the presence of bilateral adrenal myelolipomas ([Fig. 1C](#fig1){ref-type="fig"} and [D](#fig1){ref-type="fig"}). The patient's older brother had previously undergone bilateral adrenalectomies in 1989 at the age of 50 years for pathology confirmed adrenal myelolipomas. Their parents died early with unknown cause. The other family members were screened for the disease by CT or MRI, as well as hormonal testing. No abnormality was found. Figure 1Representative CT scan, MRI scan and hematoxylin and eosin (H & E) staining of the presenting patients (probands) in each family. (A) CT and MRI images showing bilateral adrenal masses in the proband for family 1. The adrenals removed during surgery are shown in the right lower corner. (B) MRI scan showing bilateral adrenal masses in the proband for family 2. (C and D) H & E staining of the masses in the proband for family 1. Magnification: ×100 (C), ×400 (D).

### Family 2

A 36-year-old woman presented to the affiliated hospital of Nanjing University of Traditional Chinese Medical with fatigue, headaches and asyndesis (unspeakable) in March 2012. She had hypokalemia since childhood and hypertension for the past 6 years. On admission, her blood pressure was 170/110 mmHg. MRI revealed bilateral adrenal masses with a signal intensity similar to that of fat, suggesting the presence of adrenal myelolipomas ([Fig. 1B](#fig1){ref-type="fig"}). Laboratory results showed increased ACTH (more than 1250 pg/mL) and decreased cortisol (less than 2 μg/dL). In April and November 2012, the patient underwent left and right adrenalectomies, respectively. Intraoperative findings showed a 20 cm × 15 cm × 10 cm mass in the left adrenal and another smaller mass in the right adrenal.

In June 2012, the patient's 32-year-old sister was referred to the affiliated hospital of Nanjing University of Traditional Chinese Medical because of increased fatigue. She had presented with fatigue 8 years before, at which time she was found to have hypokalemia. CT scan revealed a mass in her left adrenal. Laboratory results showed increased ACTH (271 pg/mL) and decreased cortisol (less than 2 μg/dL). In October 2012, she underwent left adrenalectomy, and the pathology results revealed an adrenal myelolipoma.

In July 2012, the patient's 37-year-old sister was also referred to the affiliated hospital of Nanjing University of Traditional Chinese Medical. She had hypertension and hypokalemia for the previous 3 years. CT scan revealed bilateral adrenal masses. Laboratory results showed increased ACTH (503 pg/mL) and decreased cortisol (3.1 μg/dL). In July and December 2012, she underwent left and right adrenalectomies, respectively. Pathology results confirmed the presence of adrenal myelolipomas. The other family members were asymptomatic on CT or MRI.

Identification of the mutations
-------------------------------

### Family 1

Considering the positive family history, CAH was suspected and genomic analysis was performed using DNA isolated from peripheral blood leukocytes. A compound heterozygous mutation, consisting of c.293-13C\>G and c.518T\>A, p.I173N, was identified in the*CYP12A2* gene ([Fig. 2A](#fig2){ref-type="fig"}). Sanger sequencing of the *CYP12A2* gene was conducted in the family members. The brother had the same compound heterozygous mutation as the patient. The patient's sister exhibited only the c.518T\>A, p.I173N mutation. Two of the patient's daughters had only the c.293-13C\>G mutation, while another daughter and her daughter had only the c.518T\>A, p.I173N mutation. The daughter of the patient's brother carried only the c.293-13C\>G mutation. The family pedigree is shown in [Fig. 2C](#fig2){ref-type="fig"}. Figure 2Gene sequencing data and family pedigrees. (A and B) Compound heterozygous mutations in *CYP21A2* gene in family 1 (A) and in *CYP17A1* gene in family 2 (B). (C and D) Pedigrees for families 1 (C) and 2 (D). The red arrow indicates the proband. '?' represents that the patients were not conducted with gene sequencing.

### Family 2

Considering the positive family history, CAH was suspected. Genomic sequencing of the patient revealed a compound heterozygous mutation, consisting of c.1118A\>T, p.H373L, and c.1459_1467del9, p.D487_F489del in the *CYP17A1* gene ([Fig. 2B](#fig2){ref-type="fig"}). Sanger sequencing was conducted on the family members, and the patient's two sisters were found to have the same compound heterozygous mutation. Her father and asymptomatic brother carried only the c.1118A\>T, p.H373L mutation, and her mother had only the c.1459_1467del9, p.D487_F489del mutation. The family pedigree is shown in [Fig. 2D](#fig2){ref-type="fig"}.

Discussion
==========

A few cases of CAH-associated adrenal myelolipoma have been reported previously with most of them caused by 21-OH deficiency. The second most common cause was 17-OH deficiency ([@bib11]). In the current report, two patients in family 1 presented with CAH-associated giant adrenal myelolipomas secondary to 21-OH deficiency caused by a compound heterozygous mutation (c.293-13C\>G/c.518T\>A, p.I173N). Three patients in family 2 presented with CAH-associated adrenal myelolipomas because of 17-OH deficiency resulting from a compound heterozygous mutation (c.1118A\>T, p.H373L/c.1459_1467del9, p.D487_F489del). All the four mutations have been reported to be associated with CAH, respectively ([@bib12], [@bib13], [@bib14], [@bib15]). However, no adrenal myelolipoma was found with single mutations. Here, we firstly described these two compound heterozygous mutations in two unrelated families and found that only these compound heterozygous mutations, but not the single mutation, in the *CYP* genes can result in adrenal myelolipomas.

A previous study reported that approximately 65--75% of CAH patients had compound heterozygous mutations, and the phenotype correlated with the less severely mutated allele ([@bib16]). However, our results suggest that CAH-associated adrenal myelolipomas occurred only when compound heterozygous mutations were present. In addition, the adrenal myelolipomas caused by 21-OH deficiency seemed to occur at an older age than those caused by 17-OH deficiency, as the individuals in family 1 were diagnosed with adrenal myelolipomas at approximately 50--60 years of age, whereas those in family 2 were diagnosed at 30--40 years of age. A previous report noted that most adrenal myelolipomas due to 17-OH deficiency were unilateral ([@bib11]). However, the mutations (H373L/D487_F489del) in family 2 tended to produce bilateral adrenal myelolipomas; the youngest sister presented with a tumor that was unilateral, but this may have been because of her younger age.

Notably, chronic ACTH hyperstimulation is thought to trigger metaplasia in CAH-associated adrenal myelolipomas, as more myelolipomas have been described in the setting of ACTH-excess CAH ([@bib17]). Although benign, CAH-associated adrenal myelolipomas may grow rapidly when exposed to chronically elevated ACTH levels for extended period ([@bib18]). Most patients in previous reports were either untreated or had stopped taking their CAH medications for an extended period ([@bib19]). The patients in our report were all untreated for a prolonged period of time, which led to chronic ACTH hyperstimulation and subsequent adrenal myelolipomas. Therefore, to avoid giant CAH-associated adrenal myelolipomas, it is important to identify CAH as early as possible to begin appropriate treatment and, thereby, interrupt the chronic adrenal hyperstimulation resulting from increased ACTH levels.

Although adrenal myelolipomas were seen in both families with different phenotypes. For example, hypertension and hypokalemia were observed in only family 2. The divergent phenotypes reflected the presence of mutations in different genes, *CYP21A2* and *CYP17A1*. CYP21A2 deficiency produces reduced aldosterone and cortisol and excess testosterone, whereas CYP17A1 deficiency leads to decreased cortisol and testosterone and increased aldosterone, which causes hypertension and hypokalemia ([@bib2]). In the same family, members with concurrent mutations in both alleles presented with adrenal myelolipomas, whereas individuals with either mutation in just one allele did not. This difference in tumor occurrence may be due to varying degrees of enzymatic deficiency. A previous study found that patients with severe mutations causing complete deficiency of enzymatic activity presented with severe phenotypes, whereas patients with mild mutations exhibited the non-classical form of CAH ([@bib20]). *In vitro* expression analysis demonstrated that complete deficiency of 21-hydroxylase enzymatic activity could result from multiple mutations in the *CYP21A2* gene, such as large deletion Δ707-714, Q318X and R356W mutations. These mutations could cause severe phenotypes, whereas other mutations, including P30L (89 C to T), V281L (1685 G to T) and P453S (2580 C to T) mutations, may lead to 20--60% residual enzymatic activity, which is likely to produce a moderate phenotype ([@bib20]). Furthermore, a previous study reported that patients with the classical form of CAH most commonly had an IVS2 AS-13 (A/C to G) mutation and a large deletion in the *CYP21A2* gene ([@bib20]). These results indicate that a strong genotype--phenotype correlation exists in CAH. Therefore, individuals with the compound mutations described in the current report should be treated early to avoid chronic ACTH hyperstimulation and actively monitored for adrenal myelolipomas. This highlights the importance of genetic testing and counseling in CAH-associated adrenal myelolipomas.

In conclusion, we found that compound heterozygous mutations, but not the single mutation, in the *CYP* genes can result in adrenal myelolipomas. Our finding also suggests that early diagnosis and timely treatment for chronic adrenal hyperstimulation may prevent the development of giant CAH-associated adrenal myelolipomas. In addition, genetic testing and counseling could be valuable means in dealing with CAH.
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